Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loxapine inhalation - Alexza Pharmaceuticals

Next Previous
Drug Profile

Loxapine inhalation - Alexza Pharmaceuticals

Alternative Names: Adasuve; ALXZ-004; AZ-004; Staccato Loxapine

Latest Information Update: 15 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexza Pharmaceuticals
  • Developer Alexza Pharmaceuticals; AOP Orphan Pharmaceuticals AG; Ferrer; Galenica S.A.; Teva Pharmaceuticals USA
  • Class Antipsychotics; Dibenzoxazepines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Agitation

Highest Development Phases

  • Marketed Agitation

Most Recent Events

  • 11 Dec 2025 Lee's Pharmaceutical acquires Staccato® One Breath Technology® platform and assets including intellectual property, know-how, trademarks, product pipeline, equipment, products and access to GMP facility from Alexza Pharmaceuticals
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Agitation(In adolescents, In children) in USA (Inhalation, Aerosol)
  • 26 Sep 2017 Galen acquires commercial rights in USA for loxapine inhalation powder from Alexza

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top